These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26606000)

  • 1. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
    Guo H; Jing L; Cheng Y; Atsaves V; Lv Y; Wu T; Su R; Zhang Y; Zhang R; Liu W; Rassidakis GZ; Wei Y; Nan K; Claret FX
    Hepatology; 2016 Mar; 63(3):898-913. PubMed ID: 26606000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma.
    Guo H; Lv Y; Tian T; Hu TH; Wang WJ; Sui X; Jiang L; Ruan ZP; Nan KJ
    Carcinogenesis; 2011 Dec; 32(12):1897-904. PubMed ID: 22002319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.
    Calvisi DF; Ladu S; Pinna F; Frau M; Tomasi ML; Sini M; Simile MM; Bonelli P; Muroni MR; Seddaiu MA; Lim DS; Feo F; Pascale RM
    Gastroenterology; 2009 Nov; 137(5):1816-26.e1-10. PubMed ID: 19686743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
    Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
    Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
    Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
    Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
    Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
    Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.
    Fornari F; Gramantieri L; Ferracin M; Veronese A; Sabbioni S; Calin GA; Grazi GL; Giovannini C; Croce CM; Bolondi L; Negrini M
    Oncogene; 2008 Sep; 27(43):5651-61. PubMed ID: 18521080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.
    Liu H; Hu J; Pan H; Luo D; Huang M; Xu W
    Dig Dis Sci; 2018 Jan; 63(1):155-165. PubMed ID: 29189991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
    Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
    J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
    Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
    Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma.
    Berg JP; Zhou Q; Breuhahn K; Schirmacher P; Patil MA; Chen X; Schäfer N; Höller TT; Fischer HP; Büttner R; Gütgemann I
    Hum Pathol; 2007 Nov; 38(11):1621-7. PubMed ID: 17651785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.
    Zhao R; Yang HY; Shin J; Phan L; Fang L; Che TF; Su CH; Yeung SC; Lee MH
    Cell Cycle; 2013 Mar; 12(6):935-43. PubMed ID: 23421998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.
    Lee YH; Judge AD; Seo D; Kitade M; Gómez-Quiroz LE; Ishikawa T; Andersen JB; Kim BK; Marquardt JU; Raggi C; Avital I; Conner EA; MacLachlan I; Factor VM; Thorgeirsson SS
    Oncogene; 2011 Oct; 30(40):4175-84. PubMed ID: 21499307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.
    Giovannini C; Gramantieri L; Minguzzi M; Fornari F; Chieco P; Grazi GL; Bolondi L
    Am J Pathol; 2012 Aug; 181(2):413-22. PubMed ID: 22705236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
    Hsieh YH; Su IJ; Yen CJ; Tsai TF; Tsai HW; Tsai HN; Huang YJ; Chen YY; Ai YL; Kao LY; Hsieh WC; Wu HC; Huang W
    Carcinogenesis; 2013 Feb; 34(2):475-85. PubMed ID: 23172669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
    Supriatno ; Harada K; Yoshida H; Sato M
    Int J Oncol; 2005 Sep; 27(3):627-35. PubMed ID: 16077910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
    Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
    Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma.
    Pan Y; Zhang Q; Tian L; Wang X; Fan X; Zhang H; Claret FX; Yang H
    Cancer Res; 2012 Apr; 72(7):1890-900. PubMed ID: 22350412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P57-mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma.
    Li WY; Li Q; Jing L; Wu T; Han LL; Wang Y; Yu SZ; Nan KJ; Guo H
    Liver Int; 2019 Jan; 39(1):147-157. PubMed ID: 30178471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma.
    Chen L; Yuan D; Wang GL; Wang Y; Wu YY; Zhu J
    J Korean Med Sci; 2010 Oct; 25(10):1438-42. PubMed ID: 20890423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.